GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ENCell Co Ltd (XKRX:456070) » Definitions » Capex-to-Revenue

ENCell Co (XKRX:456070) Capex-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ENCell Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

ENCell Co's Capital Expenditure for the three months ended in Dec. 2024 was ₩0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was ₩2,091.56 Mil.

Hence, ENCell Co's Capex-to-Revenue for the three months ended in Dec. 2024 was 0.00.


ENCell Co Capex-to-Revenue Historical Data

The historical data trend for ENCell Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENCell Co Capex-to-Revenue Chart

ENCell Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
0.05 2.59 0.59 0.18 0.09

ENCell Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only - - 0.06 - -

Competitive Comparison of ENCell Co's Capex-to-Revenue

For the Biotechnology subindustry, ENCell Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENCell Co's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ENCell Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where ENCell Co's Capex-to-Revenue falls into.


;
;

ENCell Co Capex-to-Revenue Calculation

ENCell Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-641.338) / 7209.317
=0.09

ENCell Co's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 2091.564
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ENCell Co  (XKRX:456070) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


ENCell Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of ENCell Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ENCell Co Business Description

Traded in Other Exchanges
N/A
Address
701 Yeongdong-daero, 11th floor, Gangnam-gu, Seoul, KOR
ENCell Co Ltd is a biopharmaceutical company. The company is engaged in conducting biopharmaceutical contract development and manufacturing (CDMO) service business and cell, gene therapy new drug development business for rare/incurable muscle diseases such as Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia.

ENCell Co Headlines

No Headlines